Fluvastatin, Rosuvastatin Added to Pegylated Interferon and Ribavirin

Completed · Phase 2

Conditions studied: Chronic Hepatitis C

In brief

Hypothesis: addition of fluvastatin will increase the cure rate of standard anti-HCV therapy. Summary: This trial is limited to veterans in Oklahoma who qualify for care with the Veterans Administration. It is a randomized control format including genotypes 1 and 3. There will also be pilot arms for HCV carriers who present for screening already on a statin, who will be allowed to stay on their current statin or switched to another statin. In all ways, standard therapy as noted on pegylated interferon and ribavirin will be given per FDA package insert.

Key facts

Study ID

NCT00487318

Run by

Bader, Ted, M.D.

People needed

40

Starts

2007-06-01

Expected to finish

2010-10-01

Last updated by the study team

2012-08-21

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Not previously treated.
• Off alcohol and marijuana for 6 months
• HCV RNA positive

You may not qualify if…

• HIV positive
• Advanced liver disease
• Advanced cardiopulmonary disease
• Chronic renal failure

Where it is running

• Veterans Administration Medical Center — Oklahoma City, Oklahoma, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.